I want to illustrate one of the real inadequacies of the Democratic substitute. In the main bill we reformed something called average wholesale price. I hope everyone knows what that is. I am going to illustrate it for you tonight. Under average wholesale price systems built into Medicare by the Democratic Party all these years, this is what happens. A person goes in for cancer therapy, a senior citizen, and the doctor needs a drug that costs $10; so the doctor buys a chemotherapy drug for $10. The patient ought to have to pay $2 under that, 20 percent co-pay under law. But that is not what happens. Under the average wholesale price system devised by Democratic administrations in the past under Medicare, this is what happens. The government has a phony average wholesale price posted. It might be $200 for that drug that only costs the doctor $10, and the poor patient has to put up 20 percent, not of the $10 but 20 percent of the $200. The patient puts up $40 for a drug that only costs the doctor $10 when the patient should have put up $2. That is called the average wholesale price system. It is rotten. It stinks. Our bill gets rid of it. And we replace it by reimbursing oncologists in America for not one time what their practice expense really ought to be reimbursed under the law, but we double it. We give them $430 million, twice what CMS estimates they ought to get.
William Tauzin: “I want to illustrate one of the real inadequacies of the Democratic substitute. In the main bill we reformed something…”
Editor's note · Context
Discussing the inadequacies of the Democratic substitute in Medicare drug pricing during a floor speech.
Share
More from William Tauzin
That is why we built an ASP, Average Sales Price, plus a percentage to give the smaller oncology units a chance to buy, in case the larger units buy at a lower price, they could at least get coverage on top of the Average Sales Price to…
Our purpose in requiring GSA to spread this incremental cost across the entire Federal fleet is, in fact, to remove the cost disincentive for some Federal agencies, to improve EPACT compliance, and to minimize the overall cost to the…
The gentleman is correct. Like you, I too want to ensure that unapproved products are available in times of emergency. And while we allow the FDA to make products available during such time of emergency, absent such emergency, current law…
I particularly also want to congratulate and thank my friend, the gentleman from Massachusetts (Mr. Markey), the ranking member of the subcommittee, and my dear friend, the gentleman from Michigan (Mr. Dingell), the dean of our House and…





